EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

The devastating consequences of mucopolysaccharidosis II (MPS II), also called Hunter syndrome, may soon become preventable ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use ...

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...

After several years of rapid experimentation, AI will enter a new chapter in 2026 that resembles an industry rather than an extended research cycle.

Agenus Inc. , a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus ...

For decades, we grabbed the little pink, blue, and yellow packets without a second thought. They were everywhere, from coffee ...

A randomized clinical trial published in Autism Research finds that cannabidiol (CBD) combined with terpenes may help reduce ...

The attrition rates for mindfulness-based interventions for chronic pain differed by session load and delivery format.